At their last quadrennial global meeting in Italy, arriving Intersex Genital Mutilators were greeted by fierce Nonviolent Intersex Protests + handed an Open Letter:
Opening Day of the ‘9th Joint Meeting’, Milano (Italy) 19.09.2013
On 14-17 September 2017 at the Washington D.C. Marriott Wardman Park Hotel, Intersex Genital Mutilators from allover the world will gather for the “10th International Meeting of Pediatric Endocrinology 2017” in order to advocate, defend and proliferate their practice, summoned by the “(Lawson Wilkins) Pediatric Endocrine Society (LW)PES”, the “European Society for Paediatric Endocrinology ESPE”, the Latin American “Sociedad Latinoamericana de Endocrinologia Pediatrica (SLEP)”, the “Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM)”, the “Arab Society of Paediatric Endocrinology and Diabetes (ASPED)”, the “Indian Society for Pediatric and Adolescent Endocrinology (ISPAE)”, the Australian and New Zealand “Australasian Paediatric Endocrine Group (APEG)”, the “Asia Pacific Endocrine Society (APPES)”, the “African Society for Pediatric and Adolescent Endocrinology (ASPAE)”, and the “Japanese Society for Pediatric Endocrinology (JSPE)”.
Intersex Protest #2 @ Opening of ‘4th I-DSD Symposium’, Glasgow (UK) 07.06.2013
(Centre with backpack: Prof Dr Olaf Hiort, Team Leader ‘EuroDSD’ and ‘DSDnet’).
And on Sunday 9/17/17 during a special meeting entitled “Controversies: Is there a role for early surgery in the management of DSD?” an official obituary on the demise of intersex human rights will be delivered by no other than ‘D$D tycoon’ Olaf Hiort (Luebeck, Germany), who under “Legal considerations” will explain how “the role and legal aspects of parental decisions regarding sex assignment and possible non‐reversible interventions for a minor” can be used as a loophole to “legally” continue practicing IGM with impunity.
Paediatric endocrinologist and geneticist Olaf Hiort, who recently at the “7th I-D$D” congress in Copenhagen shrugged off the Human Rights Watch report with a wry comment on the alleged need of “structured peer support”, has been complaining about being publicly criticised as “Intersex Genital Mutilator in Chief” in Germany for many years, protesting in vain such description would constitute “violent language” – “And what about my human rights?”
Hiort is the leader of the current multi-million IGM “research” projects “D$Dnet” and “Endo-€RN”, as well as of precursors including “Euro-D$D” and “Network Intersexuality/D$D”, which had the U.S. “National Institutes of Health (NIH)” setting up a U.S. “D$D Research Network” to “keep pace with” these EU “advances in basic and clinical DSD research”.
Olaf Hiort will not be the only IGM perpetrator in Washington to justify the ongoing mutilations, but he will be seconded by IGM colleagues from the U.S., Australia, China and the UK, and besides the above mentioned obituary Hiort will also deliver another lecture on “Disorders of sex development” at the “10th International Meeting of Pediatric Endocrinology” (see relevant programme items below after the break).
Such public endorsements of Intersex Genital Mutilations by Olaf Hiort and other prominent IGM practitioners have been opposed by repeated nonviolent intersex protests in Europe – however, so far no news have transpired that the international IGM clique would have to fear to be challenged in Washington – or will they?
Genital Mutilation on Children:
IGM @ ’10th International Meeting of Pediatric Endocrinology’
StopIGM.org documents sessions and presentations promoting and justifying Intersex Genital Mutilations (IGM) at the “10th International Meeting of Pediatric Endocrinology”, 14-17 September 2017 at the Washington D.C. Marriott Wardman Park Hotel (full programme PDF), organised by the “(Lawson Wilkins) Pediatric Endocrine Society (LW)PES”, the “European Society for Paediatric Endocrinology ESPE” and many more:
Session 1 (14:15‐15:45)
Topic Symposium: New insights in Disorder of Sex Development (DSD)
The aim of this symposium is to provide updated basic and clinical strategy using new technology and accumulated clinical data, and to pursue comprehensive approach to the diagnosis and management of DSD.
Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort
Andrew Sinclair (Australia)
Currently only 13% of patients receive an accurate genetic DSD diagnosis. Using a Massively Parallel Sequencing targeted DSD gene panel to sequence all 64 known diagnostic DSD genes and 967 candidate genes, we analyzed the largest international cohort of patients with DSD and found a total of 28 genes implicated in DSD, highlighting the genetic spectrum of this disorder. Sequencing revealed 97 previously unreported DSD gene variants. A likely genetic diagnosis was identified in 43% of patients with 46,XY DSD, a substantial increase over current practice. In patients with 46,XY disorders of androgen synthesis and action the genetic diagnosis rate reached 60%. In many cases, our findings were informative as to the likely cause of the DSD, which will facilitate clinical management. Targeted DSD gene panel represents a cost and time‐effective means of improving the genetic diagnostic capability for patients affected by DSD.
Endocrine Evaluation of Suspected XY DSD
S. Faisal Ahmed (UK)
Reaching a firm diagnosis in XY DSD is challenging. Rapid advances in diagnostic technology and an improved fundamental understanding of sex and gonadal development is now facilitating the diagnosis of these conditions. There is now a need for clearer guidance on the relative merits of biochemical versus genetic evaluation. In addition, there is a need for greater emphasis on showing that a firm diagnosis for conditions associated with XY DSD is associated with a change in clinical practice that benefits the patient. The standardisation and harmonisation of complex genetic and biochemical analyses and the gathering of patient‐centred outcome measures for such rare conditions cannot be performed without relying on international networks and registries.
Differential diagnosis and management – theory and practice
Chunxiu Gong (China)
2006‐2016 the DSD bank has registered more than 1200 cases. Include Sex chromosome DSD 126cases;46,XY DSD 1018 cases and non‐CAH 46,XX DSD 70 cases. Accept gene test about 340 cases. We diagnosed 70 cases HH and AIS 39 cases, and 46 5ARD, 24 rare types CAH 10 NR5A1 related DSD and HSD17B3 2cases.introduce my experience for their diagnosis and management
Session 3 (10:15‐11:45)
Topic Symposium: Adult consequences of pediatric endocrine disease
Disorders of sex development
Olaf Hiort (Germany)
Sexuality and overall health‐related quality of life play a major role in caring for adults with Differences of Sex Development (DSD). Sexual functioning might be impeded due to the given anatomy, surgical interventions or hormonal therapy. Novel approaches require highly specialized interdisciplinary care, including gynecological and urological management, specialized protocols for hormone therapies or replacements, and overall life‐long psychological support.
Controversies: Is there a role for early surgery in the management of DSD?
Genital surgery in the context of DSD has been heavily debated in the past decade, both indications and timing. In this session, this topic will be approached from a legal, urological, hormonal and psychological perspective, in order to make the audience familiar with the different arguments and sensitivities surrounding this subject and to provide a broad and nuanced overview. Diverging views that will become apparent during the session will be in included in the discussion.
Olaf Hiort (Germany)
In this presentation, recent developments in Germany will be discussed, and an “Expertise Report” by the German Ministry for Family presented. The German law on sex assignment at birth and the implications for patients with DSD conditions will be discussed. Furthermore, the role and legal aspects of parental decisions regarding sex assignment and possible non‐reversible interventions for a minor will be discussed.
Earl Chang (USA)
The pros and cons of early surgery in children with DSD will be explained. Technical considerations regarding early versus late surgery will be included in the discussion. The current approach to DSD surgery will be presented from a historical perspective.
Amy Wisniewski (USA)
In this lecture, insights in the psychosocial status of parents of young children with ambiguous genitalia, before and after genitoplasty, will be offered, including the impact of surgical complications on parents’ psychosocial status, as well as the difficulty of determining an underlying etiology for some children with 46,XY DSD. Finally, cosmetic outcomes as determined by parents and surgeons, in relation to parents’ psychosocial status, will be considered.
Panel discussion/Q & A (25 minutes)
• 23 UN Reprimands for IGM – and counting …
• “Harmful Medical Practice”: UN, COE, ACHPR, IACHR condemn IGM
• UN Committee for the Rights of the Child (CRC) 2015: IGM = Harmful Practice
• UN Committee against Torture (CAT) 2015: IGM = Inhuman Treatment or Torture
• UN Human Rights Committee (HRCttee) to examine IGM Practices
• UN Committee on the Rights of Persons with Disabilities (CRPD) condemns IGM
• 56th Session of Committee against Torture reprimands 4 Governments for IGM
• CAT 2011: Germany must investigate IGM practices and compensate survivors!
Intersex Genital Mutilations • 17 Most Common Forms
Human Rights Violations Of Children With Variations Of Sex Anatomy
IGM – Historical Overview • What is Intersex? • How Common are IGMs?
>>> Download PDF (3.65 MB) >>> Table of Contents
Eliminating IGM practices by holding the perpetrators accountable via well-established applicable human rights frameworks, including Inhuman Treatment and Harmful Practices – Presentation @ UN expert meeting on Intersex Human Rights